JP2013532489A - 遺伝子発現プロファイリングに基づくがん治療への応答の予測ならびにモニタリング - Google Patents

遺伝子発現プロファイリングに基づくがん治療への応答の予測ならびにモニタリング Download PDF

Info

Publication number
JP2013532489A
JP2013532489A JP2013523288A JP2013523288A JP2013532489A JP 2013532489 A JP2013532489 A JP 2013532489A JP 2013523288 A JP2013523288 A JP 2013523288A JP 2013523288 A JP2013523288 A JP 2013523288A JP 2013532489 A JP2013532489 A JP 2013532489A
Authority
JP
Japan
Prior art keywords
genes
cancer
treatment
subset
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013523288A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013532489A5 (enExample
Inventor
ピユッシュ グプタ，
テイマー ティー． オンダー，
エリック エス ランダー，
ロバート ワインバーグ，
センデュライ マニ，
Original Assignee
ザ ブロード インスティテュート， インコーポレイテッド
ホワイトヘッド インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ブロード インスティテュート， インコーポレイテッド, ホワイトヘッド インスティテュート filed Critical ザ ブロード インスティテュート， インコーポレイテッド
Publication of JP2013532489A publication Critical patent/JP2013532489A/ja
Publication of JP2013532489A5 publication Critical patent/JP2013532489A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2013523288A 2010-08-02 2011-08-02 遺伝子発現プロファイリングに基づくがん治療への応答の予測ならびにモニタリング Pending JP2013532489A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36992810P 2010-08-02 2010-08-02
US61/369,928 2010-08-02
PCT/US2011/046325 WO2012018857A2 (en) 2010-08-02 2011-08-02 Prediction of and monitoring cancer therapy response based on gene expression profiling

Publications (2)

Publication Number Publication Date
JP2013532489A true JP2013532489A (ja) 2013-08-19
JP2013532489A5 JP2013532489A5 (enExample) 2014-09-04

Family

ID=45560038

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013523288A Pending JP2013532489A (ja) 2010-08-02 2011-08-02 遺伝子発現プロファイリングに基づくがん治療への応答の予測ならびにモニタリング

Country Status (5)

Country Link
US (1) US20130260376A1 (enExample)
EP (1) EP2601315A4 (enExample)
JP (1) JP2013532489A (enExample)
CA (1) CA2806726A1 (enExample)
WO (1) WO2012018857A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017515479A (ja) * 2014-05-12 2017-06-15 ヤンセン ファーマシューティカ エヌ．ベー． 酢酸アビラテロン治療の対象となる患者を同定するための生物学的マーカー
JP2017527287A (ja) * 2014-09-03 2017-09-21 シージェイ ヘルスケア コーポレイションＣｊ Ｈｅａｌｔｈｃａｒｅ Ｃｏｒｐｏｒａｔｉｏｎ タンパク質キナーゼ阻害剤に対する感受性予測用バイオマーカー及びその用途

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140005260A1 (en) * 2012-06-28 2014-01-02 Tri-Service General Hospital Method for inhibiting cancer metastasis by amiodarone
KR101717177B1 (ko) * 2013-10-28 2017-03-16 주식회사 디앤피바이오텍 항암제 치료 반응성 및 생존 예후 예측용 마커
CN105886628B (zh) * 2016-04-29 2019-03-26 肖刻 Sprr1a基因在制备骨关节炎诊断产品中的应用
US20200071773A1 (en) * 2017-04-12 2020-03-05 Massachusetts Eye And Ear Infirmary Tumor signature for metastasis, compositions of matter methods of use thereof
CN112867495B (zh) * 2018-10-19 2024-08-20 韩国生命工学研究院 包含syt11抑制剂作为活性成分的胃癌治疗组合物
WO2020115261A1 (en) * 2018-12-07 2020-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2007084992A2 (en) * 2006-01-19 2007-07-26 The University Of Chicago Prognosis and therapy predictive markers and methods of use
WO2009033941A1 (en) * 2007-09-12 2009-03-19 Siemens Healthcare Diagnostics Gmbh A method for predicting the response of a tumor in a patient suffering from or at risk of developing recurrent gynecologic cancer towards a chemotherapeutic agent
WO2009074968A2 (en) * 2007-12-12 2009-06-18 Ecole Polytechnique Federale De Lausanne (Epfl) Method for predicting the efficacy of cancer therapy
WO2009126310A2 (en) * 2008-04-10 2009-10-15 Massachusetts Institute Of Technology Methods for identification and use of agents targeting cancer stem cells
WO2010003773A1 (en) * 2008-06-16 2010-01-14 Siemens Medical Solutions Diagnostics Gmbh Algorithms for outcome prediction in patients with node-positive chemotherapy-treated breast cancer
WO2010076322A1 (en) * 2008-12-30 2010-07-08 Siemens Healthcare Diagnostics Inc. Prediction of response to taxane/anthracycline-containing chemotherapy in breast cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140030255A1 (en) * 2010-11-03 2014-01-30 Merck Sharp & Dohme Corp. Methods of predicting cancer cell response to therapeutic agents
EP2702173A1 (en) * 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2007084992A2 (en) * 2006-01-19 2007-07-26 The University Of Chicago Prognosis and therapy predictive markers and methods of use
WO2009033941A1 (en) * 2007-09-12 2009-03-19 Siemens Healthcare Diagnostics Gmbh A method for predicting the response of a tumor in a patient suffering from or at risk of developing recurrent gynecologic cancer towards a chemotherapeutic agent
WO2009074968A2 (en) * 2007-12-12 2009-06-18 Ecole Polytechnique Federale De Lausanne (Epfl) Method for predicting the efficacy of cancer therapy
WO2009126310A2 (en) * 2008-04-10 2009-10-15 Massachusetts Institute Of Technology Methods for identification and use of agents targeting cancer stem cells
WO2010003773A1 (en) * 2008-06-16 2010-01-14 Siemens Medical Solutions Diagnostics Gmbh Algorithms for outcome prediction in patients with node-positive chemotherapy-treated breast cancer
WO2010076322A1 (en) * 2008-12-30 2010-07-08 Siemens Healthcare Diagnostics Inc. Prediction of response to taxane/anthracycline-containing chemotherapy in breast cancer

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ACTA PHARMACOLOGICA SINICA, vol. 31, JPN6017010033, May 2010 (2010-05-01), pages 601 - 608, ISSN: 0003527104 *
CARCINOGENESIS, vol. 29, no. 12, JPN7016002001, 2008, pages 2243 - 2251, ISSN: 0003359413 *
CELL, vol. 138, JPN6016027159, 2009, pages 623 - 625, ISSN: 0003359415 *
EUR ARCH OTORHINOLARYNGOL, vol. 263, JPN6017010031, 2006, pages 127 - 134, ISSN: 0003527103 *
INT. J. CANCER, vol. 119, JPN6015034026, 2006, pages 875 - 883, ISSN: 0003140111 *
JOURNAL OF PROTEOME RESEARCH, vol. 9, no. 2, JPN6016027154, 12 February 2010 (2010-02-12), pages 1007 - 1019, ISSN: 0003359412 *
OMICS A JOURNAL OF INTEGRATIVE BIOLOGY, vol. 13, no. 4, JPN6015034025, 2009, pages 345 - 354, ISSN: 0003140110 *
日薬理誌, vol. 135, no. 2, JPN6016027157, February 2010 (2010-02-01), pages 87 - 88, ISSN: 0003359414 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017515479A (ja) * 2014-05-12 2017-06-15 ヤンセン ファーマシューティカ エヌ．ベー． 酢酸アビラテロン治療の対象となる患者を同定するための生物学的マーカー
JP2017527287A (ja) * 2014-09-03 2017-09-21 シージェイ ヘルスケア コーポレイションＣｊ Ｈｅａｌｔｈｃａｒｅ Ｃｏｒｐｏｒａｔｉｏｎ タンパク質キナーゼ阻害剤に対する感受性予測用バイオマーカー及びその用途

Also Published As

Publication number Publication date
EP2601315A4 (en) 2014-01-29
EP2601315A2 (en) 2013-06-12
WO2012018857A2 (en) 2012-02-09
US20130260376A1 (en) 2013-10-03
CA2806726A1 (en) 2012-02-09
WO2012018857A3 (en) 2012-07-05
WO2012018857A8 (en) 2012-03-22

Similar Documents

Publication Publication Date Title
Zhang et al. Down-regulation of long non-coding RNA MEG3 serves as an unfavorable risk factor for survival of patients with breast cancer
JP2013532489A (ja) 遺伝子発現プロファイリングに基づくがん治療への応答の予測ならびにモニタリング
JP2013532489A5 (enExample)
JP2016536001A (ja) 肺がんのための分子診断試験
WO2008151072A1 (en) Multigene prognostic assay for lung cancer
US20110217701A1 (en) Prognostic Marker for Endometrial Carcinoma
EP2726635A1 (en) Multigene prognostic assay for lung cancer
Kowalik et al. Profiling micro RNA from nephrectomy and biopsy specimens: predictors of progression and survival in clear cell renal cell carcinoma
ES2882875T3 (es) Método de pronóstico y predicción de la recurrencia del cáncer de mama, marcadores empleados en el mismo y kit del mismo
US20130143753A1 (en) Methods for predicting outcome of breast cancer, and/or risk of relapse, response or survival of a patient suffering therefrom
WO2007034221A2 (en) Non small cell lung cancer therapy prognosis and target
Pankotai-Bodó et al. Routine molecular applications and recent advances in breast cancer diagnostics
Zhu et al. Cuprotosis clusters predict prognosis and immunotherapy response in low-grade glioma
Cai et al. High-expression of ZBP-89 correlates with distal metastasis and poor prognosis of patients in clear cell renal cell carcinoma
Liu et al. Elevated expression of Thoc1 is associated with aggressive phenotype and poor prognosis in colorectal cancer
Shao et al. The role of gene expression profiling in early-stage non-small cell lung cancer
US20130260384A1 (en) Method for determining cancer prognosis and prediction with cancer stem cell associated genes
US20150011411A1 (en) Biomarkers of cancer
US20120129711A1 (en) Biomarkers for the prognosis and high-grade glioma clinical outcome
JP2017529074A (ja) 治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法
WO2015161885A1 (en) Hepatocyte growth factor as marker of prognosis in small cell lung cancer (sclc)
Liu et al. High TROAP Expression Correlates With Shorter Survival in Patients With Glioma: A Study Based on Multiple Data Fusion Analysis
US20240384353A1 (en) Methods of treating pancreatic cancer
Osei et al. Review of novel liquid-based biomarkers for prostate cancer: towards personalised and targeted medicine
CN108676886A (zh) Ube2s作为生物标志物在肝细胞癌预后评估中的应用及含有此标记物的制剂盒

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140718

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140718

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150821

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160714

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170329